We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

The stock's fall snapped a two-day winning streak.

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report). The company’s ...

This was the stock's second consecutive day of gains.

Catalyst Pharmaceuticals' Firdapse delivers strong growth with a 37% CAGR. Click here to find out why CPRX stock is a Hold.

Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven ...

Total Revenues of $491.7 Million, Marking Another Year of Record GrowthFull Year 2024 Total Revenues Grew 23.5% YoY, Driven by ...

Handelsbanken Fonder AB grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 2.9% in the 4th ...

Catalyst Pharmaceuticals reported 2024 revenues of $491.7 million, projecting growth to $545-$565 million in 2025. Catalyst Pharmaceuticals, Inc. reported a record total revenue of $491.7 million ...

Ieq Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) during the 4th quarter, HoldingsChannel reports. The firm purchased 15,013 shares of ...

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living ...

CORAL GABLES, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results ...